A drug’s list price is visible. The path money takes between a manufacturer, pharmacy benefit manager, insurer, employer and pharmacy often is not. That asymmetry is the target of a new U.S. Department of Labor final rule announced on October 29.
It requires detailed compensation disclosures by pharmacy benefit managers and certain affiliated service providers to fiduciaries of large, self-insured employer health plans. For a sector obsessed with drug prices, the change shifts attention toward the machinery that determines what plans actually spend.
The Money Behind Prescription Benefits
The rule is rooted in the Employee Retirement Income Security Act, or ERISA. It generally applies to pharmacy benefit management service providers contracting with self-insured plans with at least 100 participants, or plans offered by employers with at least 100 employees, when expected compensation reaches $1,000.
The Labor Department describes a covered service provider broadly enough to include PBM-affiliated brokers and consultants in relevant arrangements. This is not a universal new price-control law for every prescription.
At its core is a simple proposition: an employer acting as a plan fiduciary should know whether the compensation paid to its service providers is reasonable. To evaluate that question, the employer needs more than a bundled administrative-fee figure.
What PBMs Will Have to Disclose
The final rule calls for disclosures of direct and indirect compensation, manufacturer payments, spread compensation, pharmacy recoupments, price-protection arrangements and other financial flows that can create incentives invisible in a conventional benefits proposal.
The initial disclosure must arrive reasonably before a new contract, renewal or extension. For renewals and extensions, the Labor Department considers at least 90 days in advance a reasonable benchmark.
Ongoing reports must generally arrive within 30 days after each semiannual period, or quarterly if the plan requests it. The difference between projected and actual compensation becomes an audit trail rather than a number buried in a renewal presentation.
The rule also requires an explanation when an ongoing amount exceeds the original disclosure by at least five percent, unless the parties agreed to a lower threshold.
New Audit Rights Go Beyond a Rebate Spreadsheet
Employers can request standardized machine-readable compensation information, and covered plans gain rights to audit the disclosures for accuracy.
Under the final rule, plans may conduct such an audit at least annually, with access to records, claims and transaction-level information reasonably necessary to verify the required disclosures. Relevant commercial contracts may also be examined, subject to confidentiality protections.
Covered service providers must acknowledge an audit request within ten business days and generally provide necessary information within 60 calendar days.
That is a meaningful operational obligation: transparency becomes useful only when someone can reconcile the totals against underlying activity.
Why the Rule Matters for GLP-1 Medicines
Why does this matter to obesity medicines and peptides? Because formulary placement, prior authorization, rebate structures and pharmacy networks help determine which treatments are financially accessible.
A manufacturer may offer one price, a patient may see another, and the employer financing the benefit may not understand the spread between them. Better disclosure could allow employers to ask sharper questions about whether the chosen benefit design serves members or intermediaries.
But disclosure does not automatically produce lower drug costs. A plan sponsor must have the expertise and bargaining power to use the information. Some arrangements may already be relatively transparent; others may require substantial contract revisions, data infrastructure and legal interpretation.
A machine-readable file is not self-explanatory. Employers will need to distinguish legitimate service fees from arrangements that create conflicts of interest, and they may need independent advisers to do it.
The July 2027 Timeline—and Who Is Covered
The effective date and application date should not be conflated. The Labor Department says the final rule takes effect 60 days after Federal Register publication, while the specific requirements apply to plan years beginning on or after July 1, 2027.
Separate statutory disclosure duties were clarified earlier in 2026, with a temporary good-faith enforcement approach during the transition. That gives organizations time to prepare but does not make the disclosure obligations irrelevant until the first full reporting cycle.
The rule also has boundaries. It focuses on large self-insured group health plans and specified service providers. It does not mean every small employer or fully insured plan receives the identical package of mandated reports under this final rule.
The Labor Department notes that broader statutory obligations may still apply to other service arrangements, but the detailed final-rule scope is narrower. Reporting it as a blanket nationwide PBM audit mandate would overstate the text.
Transparency Is Not the Same as Lower Prices
The most consequential change may be cultural rather than numerical. Prescription benefit spending has long been explained to employers through summaries, promises of savings and complex discount formulas.
The new rule asks intermediaries to expose more of the underlying economics. Whether that translates into better coverage, lower net spending or improved patient access will depend on enforcement and how plan fiduciaries act on what they learn.
The era of taking the rebate spreadsheet on faith may be approaching its end.
